

[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
[ Fri, Feb 23rd 2024
] - WOPRAI
Uy Ear Reiterated (ARQT) at Strong Buy with Increased Target to $16 on, Feb 23rd, 2024
Uy Ear of Mizuho, Reiterated "Arcutis Biotherapeutics, Inc." (ARQT) at Strong Buy with Increased Target from $8 to $16 on, Feb 23rd, 2024.
Uy has made no other calls on ARQT in the last 4 months.
There are 3 other peers that have a rating on ARQT. Out of the 3 peers that are also analyzing ARQT, 1 agrees with Uy's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Sean Kim of "JonesTrading" Downgraded from Strong Buy to Hold on, Wednesday, November 8th, 2023
These are the ratings of the 2 analyists that currently disagree with Uy
- Nigel Dally of "Morgan Stanley" Maintained at Buy with Decreased Target to $10 on, Monday, November 13th, 2023
- Serge Belanger of "Needham" Maintained at Strong Buy with Decreased Target to $8 on, Monday, November 6th, 2023
Contributing Sources